Assembly Biosciences, Inc. (ASMB)
Develops drugs to treat viral infections like herpes, hepatitis B, and hepatitis D.
$25.57-0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+39.0%
The outlook
ASMB is trading well below both its 50- and 200-day moving averages, sitting in the lower portion of its 52-week range. Analysts have a notably bullish average target about 96% above the current price, though the stock carries a very high trailing P/E ratio. Overall sentiment leans bearish according to current market positioning.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range38% of the way from its 52-week low to high
Price targetAvg target +96% vs current price
Analyst price target
~12-month · 4 analysts$50.00average target+95.5% vs now
Now $25.57
Low $43.00High $62.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$506.7M
52-wk high
$39.71
52-wk low
$16.90
50-day avg
$26.07
200-day avg
$29.26
Trailing P/E
319.6